| Project/Area Number |
18K09178
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56030:Urology-related
|
|---|
| Research Institution | Dokkyo Medical University |
|---|
Principal Investigator |
Ide Hisamitsu 獨協医科大学, 医学部, 教授 (00301383)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 前立腺癌 |
|---|
| Outline of Final Research Achievements |
In the prostate cancer cells, the steroidogenic acute regulatory (StAR) protein participated in testosterone composition. We identified Aryl hydrocarbon receptor (AhR) as a transcription factor in coordination with StAR expression in this study. In the examination using several prostate cancer cell lines, the signal of AhR did not give a change to increase proliferation, but acted for permeation invasion ability. Furthermore, the inhibitor of AhR affects the expression of StAR protein was found. The molecular mechanism about biological role in an evaluation of the testosterone composition ability and castration-resistant tolerance acquisition by the StAR was needed.
|
| Academic Significance and Societal Importance of the Research Achievements |
テストステロン合成の律速段階を形成するStAR蛋白質は、テストステロン合成経路の出発点であり、去勢抵抗性前立腺癌細胞の増殖においても重要な役割を担っている可能性が示唆される。しかし、StAR蛋白質の発現調整と前立腺癌細胞における去勢抵抗性獲得機構の関与の報告はこれまでほとんどない。本研究の知見を介して、前立腺癌、特に去勢抵抗性前立腺癌の増殖や浸潤、悪性化を抑制する新規治療戦略の立脚を目指す研究は独創的であり、臨床的意義が高い。
|
